Henrik Lindman
Consultant at Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerimmunterapi; Forskargrupp Henrik Lindman
- Mobile phone:
- +46 70 688 48 78
- E-mail:
- henrik.lindman@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 UPPSALA
More information is available to staff who log in.
Short presentation
MD, PhD, Ass. Professor in Oncology, Uppsala University
Department of Oncology, Akademiska sjukhuset, Senior registrar
Head of Breast Cancer service. Department of Oncology, Uppsala University Hospital
Chairman of the Uppsala-Örebro region Breast Group
Chairman of the Uppsala-Örebro region Breast Oncology Group
Vice chairman of the Swedish Breast Cancer Group (SweBCG)
Member of the board of the Swedish Association of Breast Oncologists
Publications
Recent publications
- Validation of primary and outcome data quality in a Swedish population-based breast cancer quality registry (2024)
- Human Epidermal Growth Factor Receptor 2-Targeting [68Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer. (2023)
- Next generation pan-cancer blood proteome profiling using proximity extension assay (2023)
- Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer (2023)
- Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR plus ), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients (2023)
All publications
Articles
- Validation of primary and outcome data quality in a Swedish population-based breast cancer quality registry (2024)
- Human Epidermal Growth Factor Receptor 2-Targeting [68Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer. (2023)
- Next generation pan-cancer blood proteome profiling using proximity extension assay (2023)
- Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer (2023)
- Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR plus ), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients (2023)
- Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer (2023)
- Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy (2023)
- Pre-treatment levels of inflammatory markers and chemotherapy completion rates in patients with early-stage breast cancer (2023)
- Endocrine treatment near the end of life among older women with metastatic breast cancer (2023)
- Outcome of different radiotherapy strategies after breast conserving surgery in patients with ductal carcinoma in situ (DCIS) (2023)
- Noninvasive detection of any-stage cancer using free glycosaminoglycans (2022)
- Neutrophil extracellular traps promote cancer-associated inflammation and myocardial stress. (2022)
- Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients (2022)
- Adjuvant Capecitabine for Early Breast Cancer (2022)
- Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population (2022)
- Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes - an observational cohort study in Sweden (2022)
- Hormonal contraception and risk of breast cancer and breast cancer in situ among Swedish women 15-34 years of age (2022)
- RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer (2022)
- Overall survival of patients with metastatic breast cancer in Sweden (2022)
- Does exercise intensity matter for fatigue during (neo)adjuvant cancer treatment? (2021)
- Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer (2021)
- Effects of heavy-load resistance training during (neo-)adjuvant chemotherapy on muscle cellular outcomes in women with breast cancer (2021)
- Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients (2021)
- Use of classifiers to optimise the identification and characterisation of metastatic breast cancer in a nationwide administrative registry (2021)
- Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer (2020)
- Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial (2020)
- Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1 (2020)
- Metastatic or locally advanced breast cancer patients (2019)
- Agreement between molecular subtyping and surrogate subtype classification (2019)
- Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series (2019)
- Diagnostic HER2-binding radiopharmaceutical, [Ga-68]Ga-ABY-025, for routine clinical use in breast cancer patients (2019)
- Kinetic Analysis of the HER2-binding ABY-025 Affibody Using Dynamic PET in Patients with Metastatic Breast Cancer (2018)
- U-CAN (2018)
- Abstract GS3-04: A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study) (2018)
- Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer The SOLD Randomized Clinical Trial (2018)
- Taxane Followed by Anthracycline or Vice Versa (2018)
- A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1) (2018)
- Evidence on the occurrence of brain metastases amongst deceased metastatic breast cancer patients from an Uppsala county disease registry (2018)
- Good adherence to adjuvant endocrine therapy in early breast cancer (2018)
- Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer (2018)
- The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling. (2018)
- Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative (2018)
- Omitting radiotherapy in women >= 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe (2018)
- Breast cancer in young women and prognosis (2017)
- Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (2017)
- Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer (2017)
- Clinical characteristics of CNS metastases of different breast cancer subtypes - Results from a cohort study (2017)
- Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen (2017)
- Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT. (2017)
- Long-term outcome in young women with breast cancer (2016)
- The development of the metastatic site pattern during time in different subtypes of breast cancer (2016)
- Nordic trip, a randomized phase 3 study in early triple negative breast cancer (2016)
- The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer-Further observations from the IMPACT solid study (2016)
- Time and value of chemotherapy administration burden in a Swedish hospital (2016)
- Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule Ga-68-ABY-025 in Breast Cancer Patients (2016)
- Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT (2016)
- Good manufacturing practice production of [68Ga]Ga-ABY-025 for HER2 specific breast cancer imaging. (2016)
- Is pathologic complete response (pCR) a valid marker of outcome even in large breast cancer? (2015)
- The Mutanome Engineered RNA Immuno-Therapy (MERIT) project (2015)
- Lymphoedema and health-related quality of life by early treatment in long-term survivors of breast cancer. A comparative retrospective study up to 15 years after diagnosis (2015)
- Non-invasive determination of HER2-expression in metastatic breast cancer by using Ga-68-ABY025 PET/CT. (2015)
- Mutanome Engineered RNA Immunotherapy (MERIT) (2015)
- Multicenter Reproducibility of F-18-Fluciclatide PET Imaging in Subjects with Solid Tumors (2015)
- Good manufacturing practice compliant production of a Ga-68-labelled Affibody agent for breast cancer imaging (2015)
- Breast cancer in young women - age a risk factor only in those not given chemotherapy (2014)
- Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX) (2014)
- Radiation dosimetry and tracer kinetic analysis of Ga-68-ABY025 Affibody in breast cancer patients (2014)
- Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling (2014)
- First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the In-111-ABY-025 Affibody Molecule (2014)
- Measuring HER2-expression in metastatic breast cancer using 68Ga-ABY025 PET/CT (2014)
- GMP compliant preparation of a (68)Gallium-labeled Affibody analogue for breast cancer patient examination (2014)
- Effects of adjuvant tamoxifen therapy on cardiac disease (2013)
- Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis (2013)
- Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer (2012)
- Molecular imaging using the Affibody molecule [111In]ABY-025 can identify the HER2 status in breast cancer patients (2012)
- Test-retest reproducibility of [F-18]fluciclatide PET imaging in subjects with solid tumors (2012)
- Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients (2012)
- Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer (2011)
- Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1 (2011)
- A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer (2011)
- Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease (2011)
- Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression (2010)
- Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer (2009)
- Health care costs for treatment of disseminated breast cancer (2009)
- Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer (2009)
- The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients (2009)
- Bisphosphonate treatment in primary breast cancer (2008)
- The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro (2008)
- Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer (2007)
- Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy (2007)
- Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. (2005)
- Early response of breast cancer bone metastases to chemotherapy evaluated with MR imaging (2001)
- AAV-mouse DNase I sustains long-term DNase I expression in vivo and suppresses breast cancer metastasis
